Stiripentol(Diacomit) has shown significant efficacy in Dravet syndrome (DS). However, any drug should be used with caution, and stiripentol is no exception. Understanding its precautions is essential to ensure the safety and effectiveness of patient treatment. This article will discuss in detail several aspects that need to be noted during the use of stiripentol and briefly introduce the clinical trial effects of this drug.

Precautions for stiripentol

Drowsiness and decreased appetite and weight

Patients using stiripentol may experience drowsiness, decreased appetite, and weight loss. These symptoms may be due to the drug's depressant effect on the central nervous system and its effects on gastrointestinal function. Doctors should regularly monitor the patient's weight and appetite and intervene if necessary.

Neutropenia and thrombocytopenia

Stiripentol may cause a decrease in neutrophil and platelet counts, which may increase the risk of infection and bleeding tendency. Therefore, during the use of stiripentol, hematological examinations should be performed regularly to detect and deal with these potential problems in a timely manner.

Withdrawal reaction

Sudden cessation of stiripentol may lead to withdrawal reaction, such as aggravation of epileptic seizures. Therefore, if treatment needs to be stopped, the drug dosage should be gradually reduced to avoid withdrawal reaction.

Risks for patients with phenylketonuria

Stiripentol may increase the risk of patients with phenylketonuria, so it should be used with caution and closely monitored in such patients.

Suicidal behavior and ideation

Patients using stiripentol may have suicidal ideation or behavior. Doctors should pay close attention to the patient's mental state, conduct psychological intervention in a timely manner, and adjust the treatment plan when necessary.

Clinical trial effect of stiripentol

Significantly reduce the frequency of epileptic seizures

Clinical trials have shown that stiripentol can significantly reduce the frequency of epileptic (spasm) seizures compared with placebo, with a response rate of up to 71%. This result is of great significance for patients who have been troubled by epileptic seizures for a long time. In addition, the proportion of patients with no epilepsy seizures in the stiripentol group was also significantly increased (43% vs 0, P=0.0013), further proving its efficacy.

Significant reduction in the frequency of epileptic seizures

The number of monthly epileptic seizures in the stiripentol group was significantly lower than that in the placebo group, and the reduction in the frequency of epileptic seizures was also significantly higher than that in the placebo group. These data fully demonstrate the significant advantages of stiripentol in controlling epileptic seizures.

Mild adverse reactions and good tolerance

Although stiripentol has certain adverse reactions, such as drowsiness and loss of appetite, these reactions are usually mild and controllable. 57% of patients experienced side effects after reducing the drug dose, and 75% of cases were well tolerated during the follow-up period. Only a few patients discontinued stiripentol due to adverse events.

As an effective anti-epileptic drug, stiripentol plays an important role in the treatment of specific types of epileptic seizures. Its clinical trial results are significant, which can significantly reduce the frequency of epileptic seizures and improve the quality of life of patients. During use, it is also necessary to pay attention to its possible adverse reactions and precautions.